Abstract 1487P
Background
Information and Communication Technology-based self-management support has been demonstrated to be effective in relieving symptoms for patients with advanced cancer. This study aimed to evaluate the effectiveness of a telemonitoring system for cancer pain relief in outpatients with advanced cancer in Japan.
Methods
The study was conducted between December 2019 and February 2023. This study included patients attending Tohoku University Hospital as outpatients, regularly taking opioids for cancer pain, with a mean pain NRS of ≥3 in 24 hours. Participants were randomized into intervention and control groups in a 1:1 ratio. The intervention group received telemonitoring care using the Cancer Pain Monitoring System (CAPAMOS). This comprises five components: symptom checks, medication checks, graphical records, pain booklet, and contact with a telenurse (chats, phones, and video phones). Alerts were sent to a telenurse when a patient’s symptoms worsened. The control group maintained a pain diary. An assessment of pain (NRS), quality of life (VAS), and opioid self-management scale (Opioid Self-Management Scale for Advanced Cancer Patients with Pain: OSSA) was conducted at baseline and after 2 and 4 weeks. Further, the Ethics Committee of Tohoku University Graduate School of Medicine reviewed the study (approval no. 2020-1-194).
Results
A total of 48 patients were enrolled in this study. There were no significant differences in baseline age (intervention 53.5 vs. control 57.0, p=0.68), severe pain (5.0 vs. 5.0, p=0.92), average pain (4.0 vs. 4.0, p=0.41), OSSA scores (135.0 vs. 130.0, p=0.06) and QOL (70.0 vs. 64.0, p=0.86) between groups. At 2 weeks post-intervention, no significant association was observed. At 1 month post-intervention, severe pain (5.0 vs. 5.5, p = 0.37), average pain (3.0, vs. 4.0, p = 0.41), OSSA scores (136.5 vs. 123.5, p=0.06), and QOL scores (57.5 vs. 50.0, p = 0.58) were not statistically significant. The scores for understanding pain characteristics in OSSA were significantly higher in the OSSA group than in the control group (10.0 vs. 8.0, p=0.04).
Conclusions
Telemonitoring support has led to educational advantages, such as improving patients’ understanding of opioid self-management and pain characteristics.
Clinical trial identification
UMIN000038334.
Editorial acknowledgement
Legal entity responsible for the study
Tohoku University Graduate School of Medicine.
Funding
JSPS KAKENHI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10